Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Hebei Medical University Fourth Hospital1 site in 1 country180 target enrollmentJuly 16, 2020

InterventionsCamrelizumab/sintilimab+ Standard chemotherapy Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy

DrugsCamrelizumab/sintilimab+ Standard chemotherapy Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy

Overview

Phase: Phase 2
Intervention: Camrelizumab/sintilimab+ Standard chemotherapy
Conditions: Advanced Solid Tumor
Sponsor: Hebei Medical University Fourth Hospital
Enrollment: 180
Locations: 1
Primary Endpoint: PFS
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.

Registry

clinicaltrials.gov

Start Date

July 16, 2020

End Date

April 1, 2024

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hebei Medical University Fourth Hospital

Responsible Party

Principal Investigator

Jian SHI

Principal Investigator

Hebei Medical University Fourth Hospital

Eligibility Criteria

Inclusion Criteria

•Age:18 to 70 years old;
•Patients with advanced solid tumors confirmed by histopathology or cytology and genetic testing was negative;
•None previous chemotherapy, Antiangiogenic targeted therapy, Immune checkpoint inhibitors therapy（NOTE: neoadjuvant and adjuvant therapy is allowed）;
•At least one measurable lesion (measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1);
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
•Life expectancy greater than or equal to 18 weeks;
•Major organ function has to meet the following certeria:
•For results of blood routine test HB≥90g/L; ANC≥1.5×109/L; PLT≥90×109/L; 2) For results of blood biochemical test ALB≥30g/L ALT and AST\<2.5×ULN, but\<5×ULN if the transferanse elevation is due to liver metastases； TBIL≤1.5×ULN； Serum creatinine ≤1.5×ULN;
•Left ventricular ejection fraction (LVEF) ≥50%;
•Women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 14 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. Men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks;

Exclusion Criteria

•Patients with symptomatic brain metastases;
•Subjects with immunosuppressive medications within 14 days of first administration of study treatment, prednisone is used for less than 1 week, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (no more than 10 mg / day of prednisolone or other corticosteroids of equivalent pharmaceutical physiological dose);
•The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in childhood, and patients who do not need any intervention after adulthood can be included; asthma patients who require bronchodilators for medical intervention cannot be included);
•Patients with other malignant tumors within 5 years (except for the treated skin basal cell carcinoma and cervical carcinoma in situ, dual or multiple primary tumors);
•Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV-DNA ≥1000 IU/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method) or co-infection with hepatitis B and C, requiring antiviral treatment during the study ;
•3 months before study drug administration, the following occurred: myocardial infarction, severe / unstable angina pectoris, grade III-IV cardiac insufficiency according to New York Heart Association(NYHA) criteria, uncontrolled arrhythmias (including QTcF interval male\> 450 ms, female\> 470 ms ,The QTcF interval is calculated using Fridericia formula), symptomatic congestive heart failure, cerebrovascular accidents (including transient ischemic attack or symptomatic pulmonary embolism), in stable phase, need a cardiovascular physician evaluation;
•Severe infections within 2 weeks before study drug administration (eg. Need intravenous drip antibiotics, antifungals or antivirals) or \>38.5℃during screening visits or on the first scheduled day of dosing;
•History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
•Less than 4 weeks from the last clinical trial;
•History of psychiatric drugs abuse and can't quit or patients with mental disorders;

Arms & Interventions

Group A

Intervention: Camrelizumab/sintilimab+ Standard chemotherapy

Group B

Intervention: Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）

Group C

Intervention: Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy

Outcomes

Primary Outcomes

PFS

Time Frame: evaluated in 24 months since the treatment began

Baseline to measured date of progression or death from any cause

Secondary Outcomes

Adverse events(up to 24 weeks)
ORR(tumor assessment every 6 weeks since the treatment began，up to 24 months)
DCR(tumor assessment every 6 weeks since the treatment began，up to 24 months)
OS(the first day of treatment to death or last survival confirm date,up to 24 months)